Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.73 |
| ▸ | GLP1R | P43220 | 3/20 | 0.58 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.58 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504570 | 0.91 | TFPI (0.67) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL30648448 | 0.89 | TFPI (0.70) | TFPIGLP1RVIPR1VIPR2KEAP1 | |
| SCHEMBL30607300 | 0.88 | TFPI (0.67) | TFPIGLP1RVIPR1OPRM1OPRD1 | |
| SCHEMBL29903297 | 0.88 | TFPI (0.71) | TFPIGLP1RVIPR1VIPR2 | |
| SCHEMBL30607319 | 0.88 | TFPI (0.71) | TFPIGLP1RVIPR1VIPR2 | |
| SCHEMBL29431940 | 0.88 | TFPI (0.75) | TFPIIL23RVIPR1VIPR2KEAP1 | |
| SCHEMBL22807671 | 0.88 | TFPI (0.64) | TFPIIL23RVIPR1KEAP1 | |
| SCHEMBL29372983 | 0.88 | TFPI (0.64) | TFPIIL23RVIPR1KEAP1 | |
| SCHEMBL30414079 | 0.88 | TFPI (0.63) | TFPIIL23RVIPR1VIPR2 | |
| SCHEMBL30883265 | 0.87 | TFPI (0.66) | TFPIVIPR1VIPR2KEAP1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119213061-A | Cross-linked protein, method for producing the same and use thereof | 纽约州立大学研究基金会 | 2024-12-27 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-118560442-B | Pressure control system and method for electronic stability control of vehicle body | 凯晟动力技术（嘉兴）有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118692700-A | PD-L1 inhibitor targeted therapy prognosis prediction model and construction method | 上海仁东医学检验所有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118560442-A | Pressure control system and method for electronic stability control of vehicle body | 凯晟动力技术（嘉兴）有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-12024750-B2 | Methylation markers and targeted methylation probe panel | GRAIL, LLC (US) | 2024-07-02 | — | — | US | claimed |
| US-20240180485-A1 | METHOD AND DEVICE FOR INDUCING HYPOMETABOLIC STATE IN SUBJECT WITH DISEASE | UNIVERSITY OF TSUKUBA (JP) | 2024-06-06 | — | — | US | claimed |
| WO-2024004500-A1 | UTILIZATION OF A HIBERNATION-LIKE STATE IN NEUROLOGICAL DISEASES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2024-01-04 | — | — | WO | claimed |
| CN-117098768-A | Biologically reactive compounds and methods of use thereof | 加利福尼亚大学董事会 | 2023-11-21 | — | — | CN | claimed |
| WO-2023134090-A1 | USE OF A NEUROPEPTIDE IN TREATING BONE-INJURY DISEASE | SHENZHEN INSTITUTE OF ADVANCED TECHNOLOGY (CN) | 2023-07-20 | — | — | WO | claimed |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | claimed |
| CN-115835876-A | Use of neuropeptides for the treatment of bone injury disorders | 深圳先进技术研究院 | 2023-03-21 | — | — | CN | claimed |
| CN-115478106-A | LR (low rate) based method for typing triple negative breast cancer and application thereof | 南方医科大学南方医院 | 2022-12-16 | — | — | CN | claimed |
| US-20220387546-A1 | Methods For Treating And/Or Preventing Hypersomnias | UNIVERSITE DE LAUSANNE (CH) | 2022-12-08 | — | — | US | claimed |
| CN-115424669-A | LR score-based triple negative breast cancer curative effect and prognosis evaluation model | 南方医科大学南方医院 | 2022-12-02 | — | — | CN | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-20220323761-A1 | METHOD FOR INDUCING HIBERNATION-LIKE STATE AND DEVICE SAME | UNIVERSITY OF TSUKUBA (JP) | 2022-10-13 | — | — | US | claimed |
| WO-2022210833-A1 | METHOD AND DEVICE FOR INDUCING HYPOMETABOLIC STATE IN SUBJECT WITH DISEASE | 国立大学法人 筑波大学 | 2022-10-06 | — | — | WO | claimed |
| EP-4048685-A1 | METHODS FOR TREATING AND/OR PREVENTING HYPERSOMNIAS | Université de Lausanne (CH) | 2022-08-31 | — | — | EP | claimed |
| CN-114829386-A | Method for treating and/or preventing hypersomnia | 洛桑大学 | 2022-07-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | TFPI 1843/4885GLP1R 3847/4885CCKBR 4599/4885 |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | TFPI 1843/4885GLP1R 3847/4885CCKBR 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.